← Back to Screener
Guardant Health, Inc. Common Stock (GH)
Price$129.14
Value ScoreF
Growth ScoreA
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)13.37%
Price vs S&P 500 (4W)43.08%
VGM Score61.59
Market Capitalization$17.20B
All Metrics
Book Value / Share (Quarterly)$0.57
P/TBV (Annual)21.93x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)29.76%
Cash Flow / Share (Quarterly)$-1.80
Price vs S&P 500 (YTD)16.04%
Gross Margin (TTM)64.90%
Net Profit Margin (TTM)-40.10%
EPS (TTM)$-3.40
10-Day Avg Trading Volume2.87M
EPS Excl Extra (TTM)$-3.40
Revenue Growth (5Y)27.92%
EPS (Annual)$-3.32
ROI (Annual)-36.92%
Gross Margin (Annual)64.46%
Net Profit Margin (5Y Avg)-88.13%
Cash / Share (Quarterly)$8.39
Revenue Growth QoQ (YoY)48.26%
ROA (Last FY)-20.67%
Revenue Growth TTM (YoY)39.56%
EBITD / Share (TTM)$-3.32
ROE (5Y Avg)-296.29%
Operating Margin (TTM)-42.69%
Cash Flow / Share (Annual)$-1.78
P/B Ratio249.23x
P/B Ratio (Quarterly)35.72x
Net Income / Employee (Annual)$-167,200
EV / Revenue (TTM)16.40x
Net Interest Coverage (TTM)-150.95x
ROA (TTM)-26.50%
EV / EBITDA (TTM)259.30x
EPS Incl Extra (Annual)$-3.32
Current Ratio (Annual)4.84x
Quick Ratio (Quarterly)4.25x
3-Month Avg Trading Volume2.12M
52-Week Price Return236.42%
Revenue / Employee (TTM)$433,800
Tangible BV / Share (Quarterly)$0.50
P/S Ratio (Annual)17.51x
Asset Turnover (Annual)0.49x
52-Week High$133.97
Operating Margin (5Y Avg)-87.43%
EPS Excl Extra (Annual)$-3.32
CapEx CAGR (5Y)-2.23%
Tangible BV CAGR (5Y)-31.91%
26-Week Price Return29.30%
Quick Ratio (Annual)4.42x
13-Week Price Return32.38%
Total Debt / Equity (Annual)7.18x
Current Ratio (Quarterly)4.68x
Enterprise Value$17.71B
Revenue / Share Growth (5Y)21.65%
Asset Turnover (TTM)0.66x
Book Value / Share Growth (5Y)-25.36%
Revenue / Employee (Annual)$394,400
Inventory Turnover (Annual)4.45x
Pretax Margin (Annual)-42.52%
Cash / Share (Annual)$9.20
3-Month Return Std Dev60.87%
Gross Margin (5Y Avg)63.53%
Net Income / Employee (TTM)$-174,000
ROE (Last FY)-302.14%
Net Interest Coverage (Annual)-0.76x
EPS Basic Excl Extra (Annual)$-3.32
Receivables Turnover (TTM)8.54x
Total Debt / Equity (Quarterly)16.78x
EPS Incl Extra (TTM)$-3.40
Receivables Turnover (Annual)7.92x
ROI (TTM)-34.74%
P/S Ratio (TTM)15.92x
Pretax Margin (5Y Avg)-86.91%
Revenue / Share (Annual)$7.83
Tangible BV / Share (Annual)$1.23
Price vs S&P 500 (52W)208.21%
Year-to-Date Return26.97%
5-Day Price Return9.03%
EPS Normalized (Annual)$-3.32
ROA (5Y Avg)-27.19%
Net Profit Margin (Annual)-42.39%
Month-to-Date Return48.93%
Cash Flow / Share (TTM)$-3.61
EBITD / Share (Annual)$-3.21
Operating Margin (Annual)-45.02%
LT Debt / Equity (Annual)7.18x
ROI (5Y Avg)-27.18%
LT Debt / Equity (Quarterly)16.77x
EPS Basic Excl Extra (TTM)$-3.40
P/TBV (Quarterly)40.60x
P/B Ratio (Annual)20.69x
Inventory Turnover (TTM)4.71x
Pretax Margin (TTM)-40.21%
Book Value / Share (Annual)$1.30
Price vs S&P 500 (13W)22.63%
Beta1.66x
Revenue / Share (TTM)$8.23
ROE (TTM)-246.60%
52-Week Low$38.03
vGradeF
gGradeA
mGradeA
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.45est. -0.48
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.28
4.29
4.29
4.30
Industry Peers — Health Services(28)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GHGuardant Health, Inc. Common Stock | F | A | A | $129.14 |
| NTRANatera, Inc. Common Stock | F | A | B | $218.81 |
| DGXQuest Diagnostics Inc. | C | D | C | $192.20 |
| LHLabcorp Holdings Inc. | C | D | C | $256.87 |
| EXASExact Sciences Corp | F | B | B | $0.00 |
| CELCCelcuity Inc. Common Stock | — | — | B | $122.96 |
| CAICaris Life Sciences, Inc. Common Stock | F | F | C | $16.45 |
| RDNTRadNet, Inc. Common Stock | D | C | D | $52.89 |
| VCYTVeracyte, Inc. | D | A | B | $48.18 |
| GRALGRAIL, Inc. Common Stock | D | A | B | $64.40 |
| FTREFortrea Holdings Inc. Common Stock | B | F | A | $15.76 |
About
Guardant Health is a liquid biopsy leader providing blood-based cancer tests for clinical detection and monitoring. The company's core franchises include Guardant360 for tumor genomic profiling, Reveal for molecular residual disease monitoring, and Shield for colorectal cancer screening. Guardant also offers regulatory consulting and clinical trial support services for the oncology research market.